

1 **APPENDIX**

2 **PRINCIPAL INVESTIGATORS AND CENTERS PARTICIPATING IN ECLIPSE (NCT00292552,**
3 **SC0104960)**

4 Bulgaria: Y Ivanov, Pleven; K Kostov, Sofia. Canada: J Bourbeau, Montreal;
5 M Fitzgerald, Vancouver; P Hernández, Halifax; K Killian, Hamilton; R Levy, Vancouver;
6 F Maltais, Montreal; D O'Donnell, Kingston. Czech Republic: J Krepelka, Praha.
7 Denmark: J Vestbo, Hvidovre. The Netherlands: E Wouters, Horn. New Zealand:
8 D Quinn, Wellington. Norway: P Bakke, Bergen, Slovenia: M Kosnik, Golnik. Spain:
9 A Agusti, Jaume Sauleda, Palma de Mallorca. Ukraine: Y Feschenko, Kiev; V Gavrisyuk,
10 Kiev; L Yashina, W MacNee, Edinburgh; D Singh, Manchester; J Wedzicha, London.
11 USA: A Anzueto, San Antonio, TX; S Braman, Providence, RI; R Casaburi, Torrance CA;
12 B Celli, Boston, MA; G Giessel, Richmond, VA; M Gotfried, Phoenix, AZ; G Greenwald,
13 Rancho Mirage, CA; N Hanania, Houston, TX; D Mahler, Lebanon, NH; B Make, Denver,
14 CO; S Rennard, Omaha, NE; C Rochester, New Haven, CT; P Scanlon, Rochester, MN; D
15 Schuller, Omaha, NE; F Scieurba, Pittsburg, PA; A Sharafkhaneh, Houston, TX; T Siler, St
16 Charles, MO; E Silverman, Boston, MA; A Wanner, Miami, FL; R Wise, Baltimore, MD; R
17 ZuWallack, Hartford, CT.

18

19 **Steering Committee:** H Coxson (Canada), L Edwards (GlaxoSmithKline, USA), R Tal-
20 Singer (Co-chair, GlaxoSmithKline, USA), D Lomas (UK), W MacNee (UK), E Silverman
21 (USA), C Crim (GlaxoSmithKline, USA), J Vestbo (Co-chair, Denmark), J Yates
22 (GlaxoSmithKline, USA).

1

2 **Scientific Committee:** A Agusti (Spain), P Bakke (Norway), P Calverley (UK), B Celli
3 (USA), C Crim (GlaxoSmithKline, USA), B Miller(GlaxoSmithKline, US), W MacNee (Chair,
4 UK), S Rennard (USA), R Tal-Singer (GlaxoSmithKline, USA), E Wouters (The
5 Netherlands), J Yates (GlaxoSmithKline, USA).

6

7